Travere Therapeutics’ Kidney Disorder Drug Approved by US FDA
A novel treatment for a rare kidney disease developed by Travere Therapeutics has received US FDA approval. The US FDA granted the drug, which is called sparsentan, an expedited approval for the treatment of primary immunoglobulin A nephropathy (IgAN), which is prone to rapid disease progression. The first non-immunosuppressive treatment for IgAN to be approved […]
Continue Reading